Genentech Bets On Kineta's Early-Stage, Disease-Modifying Pain Therapy

Genentech partners with the Seattle biotech on a non-opioid approach to chronic pain. Kineta says there's disease-modifying potential.

Handshake of businessmen

Genentech Inc. is taking another stab at the pain market, signing on very early to Kineta Chronic Pain LLC's nicotinic acetylcholine receptor alpha 9/10 antagonist program. The biotech thinks it may have struck on a drug target that may not only offer a safer approach to pain therapy than opioid receptor drugs, but could yield disease-modifying therapies as well.

Even though the Seattle biotech's nicotinic acetylcholine receptor alpha 9/10 (α9/α10 nAChR) antagonist is still in the preclinical stage, it...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

More from Business